Display options
Cite
Mota JM, Scaranti M, Fonseca LG, et al. Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case Rep Oncol. 2016;9(2):481-487doi: 10.1159/000448111.
Mota, J. M., Scaranti, M., Fonseca, L. G., Tolói, D. A., de Camargo, V. P., Munhoz, R. R., Feher, O., & Hoff, P. M. (2016). Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case reports in oncology, 9(2), 481-487. https://doi.org/10.1159/000448111
Mota, José Maurício, et al. "Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma." Case reports in oncology vol. 9,2 (2016): 481-487. doi: https://doi.org/10.1159/000448111
Mota JM, Scaranti M, Fonseca LG, Tolói DA, de Camargo VP, Munhoz RR, Feher O, Hoff PM. Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma. Case Rep Oncol. 2016 Aug 24;9(2):481-487. doi: 10.1159/000448111. eCollection 2016. PMID: 27721772; PMCID: PMC5043218.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2016 Aug 24;9(2):481-487. doi: 10.1159/000448111. eCollection 2016.

Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma.

Case reports in oncology

José Maurício Mota, Mariana Scaranti, Leonardo G Fonseca, Diego Araújo Tolói, Veridiana Pires de Camargo, Rodrigo Ramella Munhoz, Olavo Feher, Paulo M Hoff

Affiliations

  1. Medical Oncology Division, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.

PMID: 27721772 PMCID: PMC5043218 DOI: 10.1159/000448111

Abstract

BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an adult patient presenting with metastatic KHE of the spleen, who had a partial response after treatment with paclitaxel.

CASE PRESENTATION: A 36-year-old man presented in November 2012 with a nontraumatic rupture of the spleen. A splenectomy was performed, and the pathology was consistent with a nonspecific vascular proliferation. Follow-up scans revealed lytic bone lesions and liver metastasis. A biopsy of the liver was performed and confirmed KHE. The decision was made to proceed with treatment with gemcitabine and docetaxel, which was discontinued due to myelotoxicity. The patient was then transferred to our institution, and a pathology review supported the diagnosis of metastatic KHE. His disease remained stable until February 2014, when he developed progression in the liver. Chemotherapy was restarted with paclitaxel, and a partial response was documented after 3 cycles. Unfortunately, disease progression occurred after 24 weeks, and subsequent treatments included prednisone, doxorubicin, interferon-α, gemcitabine, and ifosfamide, without any response. The patient developed Kasabach-Merritt phenomenon and passed away 1 week later due to a major gastrointestinal bleeding.

CONCLUSIONS: This case report suggests that paclitaxel could be considered as a treatment option for advanced KHE, a rare condition for which no standard treatment exists.

Keywords: Kaposiform hemangioendothelioma; Paclitaxel; Sarcoma

References

  1. Head Neck. 2002 Jun;24(6):614-7 - PubMed
  2. J Pediatr. 2013 Jul;163(1):285-91 - PubMed
  3. J Pediatr. 1998 Mar;132(3 Pt 1):527-30 - PubMed
  4. Mod Pathol. 2005 Nov;18(11):1454-60 - PubMed
  5. Oncology. 2015;89(4):205-14 - PubMed
  6. J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):459-62 - PubMed
  7. Clin Orthop Relat Res. 2009 Sep;467(9):2464-71 - PubMed
  8. Pathol Oncol Res. 2011 Dec;17(4):969-72 - PubMed
  9. Am J Clin Pathol. 1997 Oct;108(4):450-5 - PubMed
  10. Cancer Res. 2005 Mar 15;65(6):2433-40 - PubMed
  11. J Clin Oncol. 2008 Nov 10;26(32):5269-74 - PubMed
  12. Cancer. 2012 Feb 1;118(3):770-6 - PubMed
  13. J Pediatr. 2013 Jan;162(1):142-7 - PubMed
  14. Head Neck. 2013 Aug;35(8):E258-61 - PubMed

Publication Types